

Rayfel Schneider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1742215/publications.pdf>

Version: 2024-02-01

48
papers

2,647
citations

304743

22
h-index

233421

45
g-index

48
all docs

48
docs citations

48
times ranked

2563
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	5.6	427
2	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.9	338
3	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Entesitis. <i>Arthritis Care and Research</i> , 2019, 71, 717-734.	3.4	225
4	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1854-1860.	0.9	192
5	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. <i>Arthritis Care and Research</i> , 2019, 71, 703-716.	3.4	176
6	Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: A multicenter cohort study. <i>Arthritis and Rheumatism</i> , 2000, 43, 2402-2409.	6.7	124
7	Emergent high fatality lung disease in systemic juvenile arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1722-1731.	0.9	122
8	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Entesitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 846-863.	5.6	110
9	Systemic Juvenile Idiopathic Arthritis. <i>Pediatric Clinics of North America</i> , 2018, 65, 691-709.	1.8	86
10	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1710-1719.	0.9	79
11	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1092-1098.	0.9	72
12	Juvenile rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2002, 28, 503-530.	1.9	65
13	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	3.8	57
14	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 864-877.	5.6	57
15	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. <i>Arthritis Research and Therapy</i> , 2017, 19, 13.	3.5	49
16	The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. <i>Journal of Rheumatology</i> , 2016, 43, 1755-1762.	2.0	41
17	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Pediatric Rheumatology</i> , 2017, 15, 68.	2.1	39
18	Pediatric Rheumatology Collaborative Study Group " over four decades of pivotal clinical drug research in pediatric rheumatology. <i>Pediatric Rheumatology</i> , 2018, 16, 45.	2.1	35

#	ARTICLE	IF	CITATIONS
19	The association between Turner's syndrome and juvenile rheumatoid arthritis. <i>Pediatric Radiology</i> , 1999, 29, 676-681.	2.0	34
20	Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 668-675.	0.8	31
21	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. <i>Pain</i> , 2018, 159, 57-66.	4.2	29
22	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1945-1951.	5.6	28
23	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 336-346.	5.6	23
24	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 2147-2158.	5.6	21
25	A case of pancreatitis, panniculitis and polyarthritis syndrome: Elucidating the pathophysiologic mechanisms of a rare condition. <i>Journal of Pediatric Surgery Case Reports</i> , 2015, 3, 223-226.	0.2	18
26	OPO204-EMAPALUMAB, AN INTERFERON GAMMA (IFN- γ)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJA)., 2019, , .		15
27	A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab. <i>Arthritis and Rheumatology</i> , 2014, 66, S83.	5.6	14
28	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1117-1126.	2.0	13
29	AMIGO: A Novel Approach to the Mentorship Gap in Pediatric Rheumatology. <i>Journal of Pediatrics</i> , 2014, 164, 226-227.e3.	1.8	11
30	Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey. <i>Pediatric Rheumatology</i> , 2019, 17, 48.	2.1	11
31	Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2020, 59, 2402-2411.	1.9	11
32	Proposed Core Set of Items for Measuring Disease Activity in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 115-121.	2.0	10
33	Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis – Two Ends of the Same Spectrum. <i>Frontiers in Pediatrics</i> , 2021, 9, 665815.	1.9	10
34	Efficacy of an Interinstitutional Mentoring Program Within Pediatric Rheumatology. <i>Arthritis Care and Research</i> , 2016, 68, 645-651.	3.4	9
35	It's Not Just About Getting Along: Exploring Learning Through the Discourse and Practice of Interprofessional Collaboration. <i>Academic Medicine</i> , 2020, 95, S73-S80.	1.6	9
36	Don't let up: implementing and sustaining change in a new post-licensure education model for developing extended role practitioners involved in arthritis care. <i>Journal of Multidisciplinary Healthcare</i> , 2015, 8, 389.	2.7	8

#	ARTICLE	IF	CITATIONS
37	Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. <i>Pediatric Rheumatology</i> , 2018, 16, 17.	2.1	8
38	Clinical and psychosocial stress factors are associated with decline in physical activity over time in children with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2021, 19, 97.	2.1	8
39	Systemic onset juvenile idiopathic arthritis and exposure to fine particulate air pollution. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 946-952.	0.8	8
40	A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics-A Quarternary Centre's Experience. <i>Arthritis and Rheumatology</i> , 2014, 66, S220-S221.	5.6	7
41	The patient perspective: arthritis care provided by Advanced Clinician Practitioner in Arthritis Care program-trained clinicians. <i>Open Access Rheumatology: Research and Reviews</i> , 2015, 7, 45.	1.6	6
42	Higher concentrations of vitamin D in Canadian children with juvenile idiopathic arthritis compared to healthy controls are associated with more frequent use of vitamin D supplements and season of birth. <i>Nutrition Research</i> , 2021, 92, 139-149.	2.9	5
43	A curious case of growth failure and hypercalcemia: Questions. <i>Pediatric Nephrology</i> , 2018, 33, 991-993.	1.7	3
44	A145: Faculty and Resident Perceptions About Teaching and Learning the Pediatric Musculoskeletal Examination: An Exploratory Study. <i>Arthritis and Rheumatology</i> , 2014, 66, S188.	5.6	1
45	A141: Active Engagement of Teens with Juvenile Idiopathic Arthritis in Medical Education: What Do They Think Their Contribution Might Be?. <i>Arthritis and Rheumatology</i> , 2014, 66, S184-S184.	5.6	1
46	A curious case of growth failure and hypercalcemia: Answers. <i>Pediatric Nephrology</i> , 2018, 33, 995-999.	1.7	1
47	A177: Program Evaluation of the ACR/CARRA Inter-Institutional Mentoring Program (AMIGO) in Pediatric Rheumatology. <i>Arthritis and Rheumatology</i> , 2014, 66, S231-S231.	5.6	0
48	Soluble Low-density Lipoprotein Receptor-related Protein 1 in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 760-766.	2.0	0